CalciMedica (NASDAQ: CALC) director lists 2.1M shares and capped warrant holdings
Rhea-AI Filing Summary
CalciMedica, Inc. director Evgeny Zaytsev filed an initial ownership report showing indirect holdings through Bering Partners II, L.P. Bering II holds 2,113,513 shares of common stock and a warrant for 130,651 underlying common shares at an exercise price of $7.15 per share, expiring on December 31, 2026. The warrant is subject to a beneficial ownership cap that was increased from 4.99% to 19.99% effective after notice given on July 2, 2026, limiting how much of CalciMedica’s stock can be held upon exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Zaytsev Evgeny
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrant | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Warrant — 130,651 shares (Indirect, By Bering Partners II, L.P.);
Common Stock — 2,113,513 shares (Indirect, By Bering Partners II, L.P.)
Footnotes (2)
- F1. The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.
- F2. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (ET) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 4.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. On July 2, 2026, Bering II provided notice to the Issuer to increase such percentage to 19.99%.
Key Figures
Indirect common shares held: 2,113,513 shares
Warrant underlying shares: 130,651 shares
Warrant exercise price: $7.15/share
+4 more
7 metrics
Indirect common shares held
2,113,513 shares
Common stock held by Bering Partners II, L.P. as of Form 3
Warrant underlying shares
130,651 shares
Underlying CalciMedica common stock for reported warrant
Warrant exercise price
$7.15/share
Exercise price for the reported warrant
Initial ownership cap
4.99%
Original beneficial ownership limit on warrant exercises
Revised ownership cap
19.99%
Beneficial ownership limit after Bering II’s July 2, 2026 notice
Warrant exercise start date
January 23, 2024
Date from which the warrant may be exercised
Warrant final expiry
December 31, 2026
Latest possible expiration of the warrant
Key Terms
beneficial ownership, pecuniary interest, warrant, Phase 2 clinical trial, +2 more
6 terms
beneficial ownership financial
"Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"...disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein."
warrant financial
"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of..."
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
Phase 2 clinical trial medical
"...the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury..."
A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.
acute kidney injury medical
"...planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter..."
A sudden decline in how well the kidneys remove waste and balance fluids, often developing over hours or days; think of it like an engine that abruptly loses power and can’t filter efficiently. It matters to investors because it can drive higher medical costs, alter clinical trial results, trigger regulatory scrutiny, lead to drug label changes or recalls, and affect revenue and liability for healthcare and life sciences companies.
beneficial ownership cap financial
"...would own more than 4.99% of the total number of shares of common stock of the Issuer then issued and outstanding..."
A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider holdings does CALC director Evgeny Zaytsev report on this Form 3?
The filing reports indirect ownership through Bering Partners II, L.P. of 2,113,513 CalciMedica common shares and a warrant for 130,651 underlying common shares. This establishes Zaytsev’s starting equity position as a director, without indicating any recent purchase or sale activity.
How many CalciMedica warrants are reported and what are their main terms?
The Form 3 lists a warrant linked to 130,651 CalciMedica common shares with a $7.15 exercise price. It is exercisable on or after January 23, 2024 and expires no later than December 31, 2026, subject to additional timing tied to clinical trial topline results.
What is the beneficial ownership limitation on the CALC warrant held by Bering Partners II, L.P.?
The warrant includes a cap preventing exercises that would push combined ownership above 4.99% of CalciMedica’s outstanding common stock, subject to certain exceptions. After notice given on July 2, 2026, Bering Partners II, L.P. elected to increase this cap to 19.99%.
Who actually controls the CALC securities reported on Evgeny Zaytsev’s Form 3?
The securities are held by Bering Partners II, L.P., whose general partner Bering Partners II GP, L.L.C. may have voting and dispositive power. Zaytsev and Philip Sawyer are managing members of the GP but disclaim beneficial ownership except for their pecuniary interests in the partnership.
How is the CALC warrant exercise period linked to clinical trial results?
The warrant can be exercised until the earlier of 5:00 p.m. (ET) on December 31, 2026 or 30 days after CalciMedica’s public disclosure of topline results from a planned Phase 2 acute kidney injury trial. After that point, the warrant may no longer be exercised.